Galapagos NV initiated a Phase 1 trial with GLPG3312, a first generation compound against a novel and undisclosed inflammation target class discovered by Galapagos. The Phase 1 trial is a double-blind, placebo-controlled, single-center study evaluating the efficacy, safety, tolerability, and PK/PD[1] of GLPG3312 in 76 adult healthy male volunteers.